April 8, 2025 11:31 AM EDT
Pharma
Law

No­vo Nordisk, HHS clash over ‘ne­go­ti­a­tion-el­i­gi­ble’ drugs in IRA ap­peals fight

Nicole DeFeudis

Editor

No­vo Nordisk fo­cused on a unique ar­gu­ment in fed­er­al ap­peals court on Tues­day in a case that will con­sid­er the ex­tent to which the ju­di­cia­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Mer­ck ex­plores po­ten­tial of oral pep­tides in deal with Aus­tri­an biotech

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times